miproducts


HOYA Launches VisuPro for Early Presbyopes

Image

VisuPro All Day and VisuPro Flex – HOYA’s latest additions to its lens portfolio – have been designed to help people in their late 30s to mid-40s, who are beginning to experience the gradual loss of their eyes’ ability to focus on nearby objects.1

As people enter this age group, they may begin to experience new vision challenges including eye strain, blurred vision, and headaches during close work, such as reading or using a phone. Over time, these first presbyopic symptoms can evolve from barely noticeable to a significant source of daily discomfort affecting patients’ quality of life.

According to recent research conducted by HOYA (n=7,043), 53% of existing spectacle wearers and 60% of non-spectacle wearers between 36 to 44 years have increasing problems seeing clearly in the near distance and when using digital devices.2

For spectacle wearers in this age group, single vision lenses often become insufficient. However, patients with first presbyopic symptoms may hesitate to switch to progressive lenses, due to concerns about adaptation challenges or feeling as though they’re too young for such a change. Further, current solutions fail to adequately address the needs of non-spectacle wearers, such as emmetropes, contact lens users, and patients after refractive surgery (such as LASIK) who also require near vision support. Timely intervention is a must to address vision challenges of this group.

Advanced Focus

VisuPro All Day and VisuPro Flex advanced focus spectacle lenses can be prescribed for early presbyopes, whether they are existing spectacle wearers or not. The lenses are specifically designed to support the close-up vision of early presbyopes and provide a rejuvenated vision experience and a sharp and comfortable focus at all distances, all day long.

The lenses use HOYA’s unique Binocular Harmonization Technology (BHT) that considers the prescription for the right and left eyes to calculate and harmonise the prescription in the lenses for effortless focussing, stability, and enhanced depth of vision for all wearers. The Focus Max Optimization provides additional vision support at close distance, allowing sharper and more comfortable focus during near distance activities and digital usage. It can also help reduce eye strain or visual fatigue when working with digital devices – a benefit that over two-thirds of early presbyopic patients surveyed were highly interested in.2

Contact: HOYA Account Manager

References
1. Mayo Clinic. Presbyopia. Available at: mayoclinic.org/diseases-conditions/presbyopia/symptoms-causes/syc-20363328 [accessed: January 2025].
2. HOYA data on file. International HOYA Vision Care Consumer Research 2023.


Image

Systane Complete for Dry Eye

Symptoms of dry eye can be confusing. They can range from mild irritation to severe discomfort, with varying symptoms including watering, aching, sore, and tired eyes.1,2

Systane Complete uses HP-Guar and borate in combination with nano-lipid technology to support all layers of the tear film and relieve the symptoms of all types* of dry eye for eight hours.3,4 Upon instillation, the HP-Guar and borate crosslink to form a viscoelastic meshwork.5 This meshwork forms a bandage over the ocular surface, preferentially binding to damaged areas of the cornea6 and increasing retention of the demulcents in the drop, for extended protection and lubrication.5,6

Recommend Systane Complete preservative-free lubricant eye drops for excellent dry eye relief.

Contact: Alcon (AUS) 1800 224 153 or (NZ) 0800 101 106

ANZ-SYX-2500019.*Evaporative, aqueous deficient and mixed dry eye.

References
1. Craig JP, Nelson JD, Azar DT, et al. Ocul Surf. 2017. doi: 10.1016/j.jtos.2017.08.003. 2. Bickle K et al. Ophthalmol Ther. 2024. doi: 10.1007/s40123-023-00853-3. 3. Rangarajan R, et al. J Ocul Pharmacol Ther. 2019. doi: 10.1089/jop.2018.0031. 4. Silverstein S, et al. Clin Ophthalmol. 2020. doi: 10.2147/OPTH.S263362. 5. Springs C. Dev Ophthalmol. 2010. doi: 10.1159/000315027. 6. Ng A, et al. Clin Ophthalmol. 2018. doi: 10.2147/OPTH.S150587.